Company Insights

AFJK supplier relationships

Explore interactive graphBrowse insights index
AFJK supplier relationship map

AFJK — Supplier map and what it means for investors

Aimei Health Technology Co., Ltd. (AFJK) is listed on Nasdaq as a public vehicle rooted in a health‑technology narrative but functionally operating as a SPAC-like shell while it pursues a business combination. The company currently generates no operating revenue, relies on trust‑accounted IPO proceeds and sponsor financing to preserve the SPAC structure, and monetization will only be realized after a successful combination and the transition to operating businesses. Investors should treat AFJK as a financing vehicle with near‑term counterparty and administrative risk rather than a revenue‑producing healthcare operator.

Learn more about supplier risk and counterparty mapping at https://nullexposure.com/.

What the supplier footprint tells you about AFJK’s operating posture

The relationships disclosed in public filings and press releases form a concentrated, short‑term service ecosystem supporting AFJK through the SPAC lifecycle. Key operating characteristics drawn from the record:

  • Contracting posture is short‑term and operational: the company pays monthly administrative fees (capped and extendable) for basic sponsor services rather than long‑dated supplier commitments.
  • Spend concentration is moderate but meaningful: extension fees and promissory notes place the company into the $100k–$1m spend band for preserving the trust account and extension mechanics.
  • Criticality is high for a few counterparties: transfer agent, underwriter/book‑runner, trustee mechanics and legal advisors are functionally critical to completing a business combination and maintaining listing status.
  • Maturity and stage are early/transactional: relationships are largely service‑provider and active while the SPAC pursues its deal, not long‑term supplier contracts with operating businesses.

These company-level signals indicate AFJK’s near‑term value driver is execution of a transaction and careful counterparty management, not product market traction.

Vendor-by-vendor: what the public record shows

Below are the counterparties surfaced in news and filings. Each entry is a concise, plain‑English read on role and public confirmatory source.

Continental Stock Transfer & Trust Company

Continental acts as AFJK’s transfer agent and is the operational touchpoint for holders who need to separate IPO units into ordinary shares and rights. This role was noted in a Yahoo Finance release describing unit separation mechanics (Yahoo Finance, March 9, 2026 — https://finance.yahoo.com/news/aimei-health-technology-co-ltd-213000996.html).

Spartan Capital Securities, LLC

Spartan Capital served as the sole book‑running manager of AFJK’s offering, handling the underwriting/book‑running responsibilities for the IPO. That role is reported in the same Yahoo Finance announcement on AFJK’s offering structure (Yahoo Finance, March 9, 2026).

The Nasdaq Global Market (Nasdaq)

Nasdaq is the listing venue that permitted Aimei’s units to be split and the ordinary shares and rights to trade separately beginning January 22, 2024; the exchange’s market mechanics directly affect liquidity and trading ability for public holders (Yahoo Finance, March 9, 2026).

Grandall Law Firm

Grandall Law Firm is listed among the legal advisors to AFJK in press materials tied to a proposed business combination, functioning as external counsel on transaction matters under the disclosed advisory package (GlobeNewswire press release, June 20, 2024 — https://www.globenewswire.com/news-release/2024/06/20/2901545/0/en/...).

Hunter Taubman Fischer & Li LLC

Hunter Taubman Fischer & Li LLC is disclosed as one of AFJK’s legal advisors supporting the proposed business combination, providing transaction and regulatory counsel referenced in corporate announcements (GlobeNewswire press release, June 20, 2024).

Ogier (Cayman) LLP

Ogier (Cayman) LLP is disclosed as Cayman‑oriented legal counsel in the AFJK advisor lineup, suggesting counsel coverage for offshore entity structuring related to the business combination (GlobeNewswire press release, June 20, 2024).

Aimei Health Ltd.

Aimei Health Ltd. is identified as a sponsor/payee of an unsecured promissory note used to fund an extension of the SPAC deadline, highlighting internal sponsor commitment to preserving the combination timeline and offering conversion options into private units (reported by The Globe and Mail press release summary, March 2026 — https://www.theglobeandmail.com/investing/markets/stocks/AFJK-Q/pressreleases/226864/...).

United Hydrogen Group Inc.

United Hydrogen Group Inc. participated alongside the sponsor in funding an unsecured promissory note and extension payments into the trust account, demonstrating a direct financing role in extending AFJK’s combination timeline and the option to convert note proceeds into private units (Globe and Mail press release coverage, March 2026; GlobeNewswire announcement, June 20, 2024).

Operational constraints that shape supplier risk

Public excerpts and filings provide firm‑level constraints and drive how investors should model risk:

  • Contract terms are short‑term: administrative service payments are monthly and capped (with stated extensions up to 24 months), so vendor exposure expires relatively quickly.
  • Geography is U.S.‑centric for trust mechanics: proceeds are held in a U.S. trust account invested in short‑duration government or money‑market instruments, concentrating systemic counterparty exposure domestically.
  • Role concentration favors service providers: the Sponsor supplies office, utilities and administrative services in lieu of a broad vendor roster, concentrating operational dependency.
  • Spend cadence includes discrete extension payments that have been deposited into the trust; the company has also issued promissory notes in the low‑hundreds of thousands to preserve extension rights.

Taken together, these constraints mean AFJK’s immediate commercial risk is driven by counterparty stability around the Sponsor‑Trust‑legal stack and the ability to close a business combination.

Investment implications and risk checklist

For investors and counterparties evaluating exposure to AFJK:

  • Primary value driver: successful business combination; until then, AFJK’s enterprise value is largely dependent on trust account mechanics and sponsor funding.
  • Counterparty concentration risk: a small set of service providers (transfer agent, sponsor, book‑runner, advisors) is mission‑critical — any dispute or funding shortfall has outsized impact.
  • Short contract tails lower long‑term supplier lock‑in, but increase rollover risk if sponsor support weakens.

Key actions for due diligence:

  • Validate the status of trust account deposits and extension payments with trustee records.
  • Confirm transfer agent processes for unit separation and post‑deal share movement.
  • Monitor sponsor liquidity and any convertible note terms that could dilute public holders.

If you need a structured counterparty risk brief or a supplier‑exposure dashboard for AFJK, start here: https://nullexposure.com/.

Bottom line

AFJK is a publicly‑listed financing vehicle positioned to convert into an operating health‑tech concern only after a business combination. Investor focus should be on execution risk and counterparty robustness (sponsor funding, trustee mechanics, and legal/underwriting support) rather than current product economics. For investors and operators building exposure models, the right questions are about duration of sponsor support, the status of trust funds, and the conversion mechanics of any extension financing.

Take the next step—get a tailored supplier risk assessment at https://nullexposure.com/.